Progyny (NASDAQ:PGNY) Director Sells $137,445.00 in Stock

Progyny, Inc. (NASDAQ:PGNY) Director Kevin Gordon sold 5,500 shares of Progyny stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $24.99, for a total transaction of $137,445.00. Following the sale, the director owned 9,318 shares in the company, valued at $232,856.82. This represents a 37.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Progyny Stock Performance

Progyny stock traded down $0.12 during midday trading on Friday, hitting $25.57. 1,307,342 shares of the company’s stock were exchanged, compared to its average volume of 1,555,858. Progyny, Inc. has a 12-month low of $16.10 and a 12-month high of $28.75. The stock has a market cap of $2.00 billion, a price-to-earnings ratio of 33.21, a price-to-earnings-growth ratio of 1.35 and a beta of 0.91. The firm’s 50 day simple moving average is $19.68 and its 200 day simple moving average is $22.22.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.26 by $0.24. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The company had revenue of $328.50 million for the quarter, compared to the consensus estimate of $326.47 million. During the same period last year, the firm posted $0.17 EPS. Progyny’s revenue for the quarter was down 26.4% on a year-over-year basis. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. On average, equities research analysts forecast that Progyny, Inc. will post 1.12 EPS for the current fiscal year.

Progyny declared that its Board of Directors has initiated a stock buyback program on Tuesday, May 26th that allows the company to buyback $200.00 million in outstanding shares. This buyback authorization allows the company to repurchase up to 10.3% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board believes its stock is undervalued.

Institutional Trading of Progyny

Hedge funds and other institutional investors have recently made changes to their positions in the company. Wellington Management Group LLP lifted its stake in shares of Progyny by 260.9% in the fourth quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock valued at $57,607,000 after purchasing an additional 1,621,688 shares during the period. Fort Washington Investment Advisors Inc. OH lifted its stake in shares of Progyny by 46.9% in the first quarter. Fort Washington Investment Advisors Inc. OH now owns 2,693,393 shares of the company’s stock valued at $45,734,000 after purchasing an additional 859,289 shares during the period. Loomis Sayles & Co. L P acquired a new stake in shares of Progyny in the fourth quarter valued at about $19,917,000. Barclays PLC lifted its stake in shares of Progyny by 79.2% in the third quarter. Barclays PLC now owns 1,575,470 shares of the company’s stock valued at $33,904,000 after purchasing an additional 696,447 shares during the period. Finally, Ameriprise Financial Inc. lifted its stake in shares of Progyny by 37.6% in the second quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock valued at $43,933,000 after purchasing an additional 545,431 shares during the period. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on PGNY shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Progyny in a report on Friday, March 27th. KeyCorp lowered their target price on shares of Progyny from $32.00 to $28.00 and set an “overweight” rating on the stock in a report on Monday, March 2nd. Wall Street Zen raised shares of Progyny from a “hold” rating to a “buy” rating in a report on Saturday, April 18th. BTIG Research lowered their target price on shares of Progyny from $35.00 to $30.00 and set a “buy” rating on the stock in a report on Thursday, March 5th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Progyny in a report on Monday, May 11th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, Progyny has a consensus rating of “Moderate Buy” and a consensus price target of $29.55.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.